
The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss how MET status and other factors can help inform sequencing decisions in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss how resistance mechanisms shape treatment sequencing strategies in EGFR-mutated non–small cell lung cancer. Rosner reviews common drivers of disease progression, including MET amplification and other molecular alterations that may emerge following EGFR-targeted therapy. Alder explains how repeat molecular testing and evolving tumor biology can guide subsequent treatment decisions and help optimize therapeutic sequencing.






